Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
Identifieur interne : 001303 ( Istex/Corpus ); précédent : 001302; suivant : 001304Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
Auteurs : Shin-Ichi Tamura ; Hideki Asanuma ; Yuji Ito ; Keiko Yoshizawa ; Takashi Nagamine ; Chikara Aizawa ; Takeshi KurataSource :
- Vaccine [ 0264-410X ] ; 1994.
English descriptors
- Teeft :
- Antigenic, Antigenic drift, Bronchoalveolar, Bronchoalveolar site, Bronchoalveolar wash, Bronchoalveolar washes, Challenge virus, Cholera, Cholera toxin, Drift virus vaccine, Drift viruses, Earliest virus, Earliest virus strains, Hin1, Immunization, Infection, Influenza, Influenza vaccine, Influenza virus infection, Influenza viruses, Inoculation, Intranasal, Intranasal vaccination, Intranasally, Latest virus strains, Lethal dose, Lung infection, Many changes, Mouse, Nasal, Nasal infection, Nasal site, Nasal vaccination, Nasal wash, Original antigenic, Other details, Other hand, Present results, Primary immunization, Primary inoculation, Primary vaccine, Regimen, Respiratory tract, Second antigen, Second immunization, Second inoculation, Second vaccine, Subsequent inoculation, Subtype, Tamura, Titre, Vaccinated, Vaccinated mice, Vaccination, Vaccine, Vaccine strains, Virus, Virus challenge, Virus infection, Virus strains, Virus titres, Virus vaccine.
Abstract
Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.
Url:
DOI: 10.1016/0264-410X(94)90094-9
Links to Exploration step
ISTEX:8D1DC3B6C29BAF110C167CE2FC616DC687931CE3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title><author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Asanuma, Hideki" sort="Asanuma, Hideki" uniqKey="Asanuma H" first="Hideki" last="Asanuma">Hideki Asanuma</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ito, Yuji" sort="Ito, Yuji" uniqKey="Ito Y" first="Yuji" last="Ito">Yuji Ito</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yoshizawa, Keiko" sort="Yoshizawa, Keiko" uniqKey="Yoshizawa K" first="Keiko" last="Yoshizawa">Keiko Yoshizawa</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name><affiliation><mods:affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</mods:affiliation></affiliation></author><author><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name><affiliation><mods:affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D1DC3B6C29BAF110C167CE2FC616DC687931CE3</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1016/0264-410X(94)90094-9</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001303</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001303</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title><author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Asanuma, Hideki" sort="Asanuma, Hideki" uniqKey="Asanuma H" first="Hideki" last="Asanuma">Hideki Asanuma</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ito, Yuji" sort="Ito, Yuji" uniqKey="Ito Y" first="Yuji" last="Ito">Yuji Ito</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yoshizawa, Keiko" sort="Yoshizawa, Keiko" uniqKey="Yoshizawa K" first="Keiko" last="Yoshizawa">Keiko Yoshizawa</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name><affiliation><mods:affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</mods:affiliation></affiliation></author><author><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name><affiliation><mods:affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name><affiliation><mods:affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="310">310</biblScope><biblScope unit="page" to="316">316</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antigenic</term><term>Antigenic drift</term><term>Bronchoalveolar</term><term>Bronchoalveolar site</term><term>Bronchoalveolar wash</term><term>Bronchoalveolar washes</term><term>Challenge virus</term><term>Cholera</term><term>Cholera toxin</term><term>Drift virus vaccine</term><term>Drift viruses</term><term>Earliest virus</term><term>Earliest virus strains</term><term>Hin1</term><term>Immunization</term><term>Infection</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza virus infection</term><term>Influenza viruses</term><term>Inoculation</term><term>Intranasal</term><term>Intranasal vaccination</term><term>Intranasally</term><term>Latest virus strains</term><term>Lethal dose</term><term>Lung infection</term><term>Many changes</term><term>Mouse</term><term>Nasal</term><term>Nasal infection</term><term>Nasal site</term><term>Nasal vaccination</term><term>Nasal wash</term><term>Original antigenic</term><term>Other details</term><term>Other hand</term><term>Present results</term><term>Primary immunization</term><term>Primary inoculation</term><term>Primary vaccine</term><term>Regimen</term><term>Respiratory tract</term><term>Second antigen</term><term>Second immunization</term><term>Second inoculation</term><term>Second vaccine</term><term>Subsequent inoculation</term><term>Subtype</term><term>Tamura</term><term>Titre</term><term>Vaccinated</term><term>Vaccinated mice</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine strains</term><term>Virus</term><term>Virus challenge</term><term>Virus infection</term><term>Virus strains</term><term>Virus titres</term><term>Virus vaccine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>bronchoalveolar</json:string><json:string>antigenic</json:string><json:string>tamura</json:string><json:string>virus infection</json:string><json:string>influenza</json:string><json:string>intranasally</json:string><json:string>nasal</json:string><json:string>immunization</json:string><json:string>second vaccine</json:string><json:string>hin1</json:string><json:string>vaccinated</json:string><json:string>virus</json:string><json:string>regimen</json:string><json:string>cholera toxin</json:string><json:string>virus titres</json:string><json:string>virus vaccine</json:string><json:string>virus strains</json:string><json:string>second inoculation</json:string><json:string>inoculation</json:string><json:string>earliest virus</json:string><json:string>primary vaccine</json:string><json:string>lung infection</json:string><json:string>lethal dose</json:string><json:string>influenza viruses</json:string><json:string>nasal site</json:string><json:string>primary immunization</json:string><json:string>second immunization</json:string><json:string>second antigen</json:string><json:string>nasal infection</json:string><json:string>respiratory tract</json:string><json:string>bronchoalveolar site</json:string><json:string>challenge virus</json:string><json:string>virus challenge</json:string><json:string>bronchoalveolar wash</json:string><json:string>latest virus strains</json:string><json:string>vaccination</json:string><json:string>cholera</json:string><json:string>intranasal</json:string><json:string>present results</json:string><json:string>earliest virus strains</json:string><json:string>subsequent inoculation</json:string><json:string>vaccinated mice</json:string><json:string>vaccine strains</json:string><json:string>antigenic drift</json:string><json:string>nasal vaccination</json:string><json:string>drift viruses</json:string><json:string>drift virus vaccine</json:string><json:string>bronchoalveolar washes</json:string><json:string>nasal wash</json:string><json:string>original antigenic</json:string><json:string>influenza virus infection</json:string><json:string>other hand</json:string><json:string>other details</json:string><json:string>influenza vaccine</json:string><json:string>primary inoculation</json:string><json:string>intranasal vaccination</json:string><json:string>many changes</json:string><json:string>mouse</json:string><json:string>subtype</json:string><json:string>titre</json:string><json:string>infection</json:string></teeft></keywords><author><json:item><name>Shin-ichi Tamura</name><affiliations><json:string>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</json:string></affiliations></json:item><json:item><name>Hideki Asanuma</name><affiliations><json:string>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</json:string></affiliations></json:item><json:item><name>Yuji Ito</name><affiliations><json:string>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</json:string></affiliations></json:item><json:item><name>Keiko Yoshizawa</name><affiliations><json:string>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</json:string></affiliations></json:item><json:item><name>Takashi Nagamine</name><affiliations><json:string>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</json:string></affiliations></json:item><json:item><name>Chikara Aizawa</name><affiliations><json:string>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</json:string></affiliations></json:item><json:item><name>Takeshi Kurata</name><affiliations><json:string>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Influenza vaccine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>intranasal vaccination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cholera toxin B subunit</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cross-protection</value></json:item></subject><arkIstex>ark:/67375/6H6-R0HTHJ49-6</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Short communication</json:string></originalGenre><abstract>Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.</abstract><qualityIndicators><score>8.457</score><pdfWordCount>4285</pdfWordCount><pdfCharCount>28201</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>576 x 836 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>181</abstractWordCount><abstractCharCount>1261</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title><pmid><json:string>8178552</json:string></pmid><pii><json:string>0264-410X(94)90094-9</json:string></pii><genre><json:string>brief-communication</json:string></genre><serie><title>Virology</title><language><json:string>unknown</json:string></language><pages><first>1091</first><last>1152</last></pages></serie><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>1994</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0224-1</json:string></pii><volume>12</volume><issue>4</issue><pages><first>310</first><last>316</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1-23-1</json:string><json:string>1994</json:string><json:string>5-9-1</json:string><json:string>1933</json:string></date><geogName></geogName><orgName><json:string>Department of Pharmacology, Science University of Tokyo and Professor</json:string><json:string>Butterworth-Heinemann Ltd</json:string><json:string>Kitasato Institute, Tokyo, Japan</json:string><json:string>Nihon University</json:string><json:string>National Institute of Health, Japan, Professor Y</json:string><json:string>Sigma Chemical Co.</json:string><json:string>Seikagaku Kogyo Co.</json:string><json:string>Chemo-Sero Therapeutic Research Institute, Kumamoto, Japan</json:string><json:string>Japan SLC Inc</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Director-General</json:string><json:string>K. Miyanomae</json:string><json:string>F. Koide</json:string><json:string>Dr A. Oya</json:string></persName><placeName><json:string>Toyama</json:string><json:string>Bangkok</json:string><json:string>Taiwan</json:string><json:string>MO</json:string><json:string>Kumamoto</json:string><json:string>Japan</json:string><json:string>Tokyo</json:string><json:string>Hamamatsu</json:string><json:string>St Louis</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>S. Tamura et al.</json:string><json:string>Davenport et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-R0HTHJ49-6</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - techniques d'exploration et de diagnostic (generalites)</json:string></inist></categories><publicationDate>1994</publicationDate><copyrightDate>1994</copyrightDate><doi><json:string>10.1016/0264-410X(94)90094-9</json:string></doi><id>8D1DC3B6C29BAF110C167CE2FC616DC687931CE3</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1994</date></publicationStmt><notesStmt><note type="brief-communication" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title><author xml:id="author-0000"><persName><forename type="first">Shin-ichi</forename><surname>Tamura</surname></persName><affiliation>To whom correspondence should be addressed.</affiliation><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Hideki</forename><surname>Asanuma</surname></persName><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Yuji</forename><surname>Ito</surname></persName><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Keiko</forename><surname>Yoshizawa</surname></persName><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Takashi</forename><surname>Nagamine</surname></persName><affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Chikara</forename><surname>Aizawa</surname></persName><affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Takeshi</forename><surname>Kurata</surname></persName><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation></author><idno type="istex">8D1DC3B6C29BAF110C167CE2FC616DC687931CE3</idno><idno type="ark">ark:/67375/6H6-R0HTHJ49-6</idno><idno type="DOI">10.1016/0264-410X(94)90094-9</idno><idno type="PII">0264-410X(94)90094-9</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0224-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994"></date><biblScope unit="volume">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="310">310</biblScope><biblScope unit="page" to="316">316</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1994</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Influenza vaccine</term></item><item><term>intranasal vaccination</term></item><item><term>cholera toxin B subunit</term></item><item><term>cross-protection</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993-06-14">Modified</change><change when="1994">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="sco"><item-info><jid>JVAC</jid><aid>94900949</aid><ce:pii>0264-410X(94)90094-9</ce:pii><ce:doi>10.1016/0264-410X(94)90094-9</ce:doi><ce:copyright type="unknown" year="1994"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</ce:title><ce:author-group><ce:author><ce:given-name>Shin-ichi</ce:given-name><ce:surname>Tamura</ce:surname><ce:cross-ref refid="COR1"><ce:sup>‡</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Hideki</ce:given-name><ce:surname>Asanuma</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Yuji</ce:given-name><ce:surname>Ito</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Keiko</ce:given-name><ce:surname>Yoshizawa</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Takashi</ce:given-name><ce:surname>Nagamine</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Chikara</ce:given-name><ce:surname>Aizawa</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Takeshi</ce:given-name><ce:surname>Kurata</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>‡</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="17" month="3" year="1993"></ce:date-received><ce:date-revised day="14" month="6" year="1993"></ce:date-revised><ce:date-accepted day="17" month="6" year="1993"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Influenza vaccine</ce:text></ce:keyword><ce:keyword><ce:text>intranasal vaccination</ce:text></ce:keyword><ce:keyword><ce:text>cholera toxin B subunit</ce:text></ce:keyword><ce:keyword><ce:text>cross-protection</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title></titleInfo><name type="personal"><namePart type="given">Shin-ichi</namePart><namePart type="family">Tamura</namePart><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation><description>To whom correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hideki</namePart><namePart type="family">Asanuma</namePart><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yuji</namePart><namePart type="family">Ito</namePart><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Keiko</namePart><namePart type="family">Yoshizawa</namePart><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Takashi</namePart><namePart type="family">Nagamine</namePart><affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chikara</namePart><namePart type="family">Aizawa</namePart><affiliation>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Takeshi</namePart><namePart type="family">Kurata</namePart><affiliation>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="Short communication" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1994</dateIssued><dateModified encoding="w3cdtf">1993-06-14</dateModified><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.</abstract><note type="content">Section title: Paper</note><subject><genre>Keywords</genre><topic>Influenza vaccine</topic><topic>intranasal vaccination</topic><topic>cholera toxin B subunit</topic><topic>cross-protection</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1994</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0224-1</identifier><part><date>1994</date><detail type="volume"><number>12</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="issue-pages"><start>291</start><end>384</end></extent><extent unit="pages"><start>310</start><end>316</end></extent></part></relatedItem><identifier type="istex">8D1DC3B6C29BAF110C167CE2FC616DC687931CE3</identifier><identifier type="ark">ark:/67375/6H6-R0HTHJ49-6</identifier><identifier type="DOI">10.1016/0264-410X(94)90094-9</identifier><identifier type="PII">0264-410X(94)90094-9</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001303 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001303 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8D1DC3B6C29BAF110C167CE2FC616DC687931CE3
|texte= Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
}}
| This area was generated with Dilib version V0.6.33. |  |